We have been involved in MS since 2015 through our Assessa PML collaboration with Biogen. Multiple Sclerosis is a condition that affects the brain and spinal cord. It is the most common autoimmune disorder of the central nervous system, affecting around 2.3 million people globally as of 2015. Ongoing research is focused on developing more effective disease-modifying and symptomatic treatments as well as the creation of therapies for the progressive types of MS.